and an electrographic and witnessed seizure with cessation of postictal electrocorticography (ECoG) activity associated with apnea and pulselessness (n = 1). Significance: The SUDEP rate of 2.0/1000 patient stimulation years among patients treated with the RNS System is favorable relative to treatment-resistant epilepsy patients randomized to the placebo arm of add-on drug studies or with seizures after resective surgery. Our findings support that treatments that reduce seizures reduce SUDEP risk and that not all SUDEPs follow seizures.
| INTRODUCTION
Sudden unexpected death in epilepsy (SUDEP) is the most common cause of epilepsy-related death, with an incidence (per 1000-patient-years) that rises with epilepsy severity: 0.9-2.3 in the community, 3.2-5.9 among treatmentresistant epilepsy (TRE) populations, and 6.3-9.3 among patients considered for epilepsy surgery populations. 1, 2 Most witnessed SUDEPs have occurred following seizures, especially generalized tonic-clonic seizures (GTCS) 2, 3 and interventions to reduce seizure frequency and severity are the most effective preventive strategy. 4, 5 The RNS System (NeuroPace, Mountain View, CA, USA) is a targeted direct brain responsive neurostimulator that is approved by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy for adults (≥18 years) with TRE with frequent and disabling partial onset seizures localized to no more than 2 epileptogenic foci. 6, 7 The neurostimulator detects and stimulates in response to electrocorticographic activity identified by the physician, such as epileptiform activity and electrographic seizures. The time, duration, and location of detections are stored, as are samples of the electrocorticography (ECoG) based on specific types of electrocorticographic detections, prespecified schedules, or patient or caregiver identified clinical events (marked by magnet activation). The RNS System reduces seizure frequency, 7 and therefore, like other antiseizure therapies, could reduce SUDEP risk. In addition, because the RNS System can also record objective data on the timing of seizures and seizure-like ECoG, the device can potentially elucidate SUDEP mechanisms by providing electrophysiological signals in the hours prior to death.
| METHODS
All patients treated either as part of clinical trials (N = 256) or as part of clinical care following FDA approval (N = 451) through May 5, 2016, were included in the analysis (total N = 707). As part of the clinical trials and postapproval monitoring, all deaths in patients implanted with the RNS System are reported and investigated. In all deaths, efforts are made to retrieve and interrogate the neurostimulator, obtain autopsy reports when available, and review the circumstances surrounding death. All patient deaths are assessed by a SUDEP adjudication committee comprising an epileptologist-epidemiologist, a second epileptologist, and a pathologist-medical examiner who review all available medical and forensic records related to the terminal event. The committee reaches a conclusion, using Annegers criteria, as to whether the death was possibly, probably, or definitely related to SUDEP or was not SUDEP. 8 In our analyses, rates of probable and definite SUDEP were calculated according to total implant and stimulation years (time when the device was delivering therapy). SUDEP rates and 95% confidence intervals (CIs) were used. Those deaths determined to be probable and definite SUDEP were included in the analysis. Age-adjusted standardized mortality ratios (SMRs) were calculated based on expected death rates per 10-year age group for the United States using 2007 estimates. 9 3 | RESULTS Demographic data were available for patients studied in the clinical trials (N = 256) and were presented previously. There were 14 deaths across the 707 patients with a total of 2208 years of postimplantation follow-up (data cutoff 5/5/2016). Age-adjusted SMR for all-cause mortality was 2.15 (95% CI 1.22-3.52). Causes of death were the following: suicide (n = 2; both had prior depression; 1 was no longer treated with the RNS System), status epilepticus (n = 1; patient had subtherapeutic AED levels), lymphoma (n = 1), colon cancer (n = 1), respiratory failure (n = 1), and aspiration pneumonia (n = 1). There were 2 possible, 1 probable, and 4 definite SUDEP events. The rates of probable or definite SUDEP are shown in Table 1 . As of the cut-off date, there have been no additional SUDEP cases in patients who received the device after FDA approval. The rate of probable and definite SUDEP for patients studied in the clinical trials was 2.4 per 1000 patient stimulation years (95% CI 0.9-6.4). For all patients treated with the RNS System (including those first treated after FDA approval), the rate of probable or definite SUDEP was 2.0 per 1000 (95% CI 0.7-5.2) over 2036 patient stimulation years and 2.3 per 1000 (95% CI: 0.9-5.4) over 2208 patient implant years (ie, the latter also includes patients in whom the device was implanted but not enabled for stimulation). Within the 707 patients, the age-adjusted SMR for definite and probable SUDEP was 0.75 (95% CI 0.27-1.65).
Patient characteristics for the 7 possible, probable, or definite SUDEP cases are shown in Table 2 . Of these
Key Points
• We identified 5 probable or definite SUDEPs among 707 RNS patients followed for 2208 postimplantation year
• ECoG studies around death were available for 4/ 5 SUDEPs and revealed frequent epileptiform activity or a seizure in three-fourths
• The SUDEP rate of 2.0/1000 patient stimulation years among RNS System patients is favorable for other treatment-resistant epilepsy groups
• Our findings support the idea that not all SUDEPs follow seizures and that improved seizure control can reduce SUDEP risk patients, 3 (Patients 2, 5, and 6) had a greater than 50% reduction in seizures relative to baseline in the final 3 months of life. Five patients had responsive stimulation enabled at the time of death. Two patients had responsive stimulation disabled at the time of death, either to evaluate the effect of responsive stimulation on seizure frequency, or because additional detection information was desired prior to enabling responsive stimulation. Figure 1 summarizes the RNS System data that are available from Patients 2-7 around the time of death. Patient 1 was buried before neurostimulator data could be obtained.
Patient 2 had no detections after the most recent personal contact 5 hours before being found dead. Patient 3 had increased detections and one electrographic seizure in the hour before detections ceased. Patient 4 had increased detections and 3 episodes during which the electrocorticographic activity caused a saturation of the amplifiers (electrographic seizures) in the 3 hours before detections ceased. Figure 1A shows that at approximately 19:00, the number and duration of detected episodes increased. The ECoG at 21:45 triggered by detection of a prolonged episode indicative of an electrographic seizure (Long Episode; Figure 1B4a ) was typical of the patient's clinical seizures and included 3 saturations. Three minutes later, the magnet stored ECoG at 21:48 (Figure 1B4b) showed severe suppression of ECoG activity punctuated by intermittent bursts of activity. A scheduled ECoG stored approximately 6 hours later (Figure 1B4c ), after the patient was declared dead, showed electrocerebral silence. Patient 5 had a somewhat increased detection rate, 2 long episodes, and 5 saturations in the 5 hours before detections ceased. Patient 6 had an increased detection rate, increased episode durations, and 6 saturations in the 3 hours before detections ceased. Patient 7 had a decreased detection rate starting 3 hours before death, and shorter detection episodes starting 1 hour before detections ceased.
| DISCUSSION
We identified 5 probable or definite SUDEP events among patients implanted with the RNS System. The overall SUDEP rate in this population was 2.0 per 1000 patient years for those actively treated with responsive stimulation. Three of the 5 SUDEP cases had increased epileptiform activity in the hours prior to death. One decedent had both clinical and electrographic evidence of seizures before death, whereas 2 others had increased detections supportive of electrographic seizures but lack of witnessed clinical seizures or stored ECoG precluded confirmation. Notably, 1 subject did not demonstrate any evidence of electrographic seizures or increased epileptiform activity prior to death.
The data obtained from SUDEP decedents treated with the RNS System supports the heterogenous mechanisms of SUDEP. Most SUDEP witnessed in the hospital or in the community follows an observed seizure. 2, 3 In many unwitnessed cases there is circumstantial evidence of a terminal seizure (tongue bite, etc.). 8 However, in a minority of witnessed SUDEP cases there is no clinical seizure prior to death; a recent report described 3 sudden deaths in patients with epilepsy who were undergoing electroencephalography (EEG) monitoring without evidence of a terminal electrographic seizure. 10 In all 3 cases, autopsy revealed no structural or toxicological cause of death, and they were classified as definite SUDEP according to Nashef et al.
(2012) criteria. 8 In this series, 1 SUDEP case also had no electrographic evidence of terminal seizure recorded on the RNS System. Although the patient may have had a seizure arise in a cerebral location not sampled by the device, it was likely that this SUDEP was seizure-independent. Sudden cardiac death due to arrhythmia may be responsible for a minority of SUDEPs. Indeed, a recent series examining whole-exome sequencing in SUDEP cases demonstrated that 7% of decedents had mutations in genes associated with long-QT syndrome, 11 a cause of lethal cardiac arrhythmias.
Mortality rates are substantially increased in persons with epilepsy, and SUDEP is a common, although poorly understood, cause of death. SUDEP rates are highest for those with more severe epilepsy. The risk for SUDEP is higher with medically intractable partial onset and secondarily generalized seizures, and in patients with frequent seizures, a long duration of epilepsy, and taking a large number of AEDs. 12, 13 These clinical risk factors are | 559 common in patients undergoing surgical treatment of their epilepsy, as well as treatment with neurostimulation. Treatments that reduce seizure frequency appear to reduce the risk for SUDEP. Although the populations studied have key differences, the SUDEP rate of 2.0 per 1000 patient stimulation years (95% CI 0.7-5.2) among patients undergoing treatment with responsive stimulation is favorable relative to TRE patients randomized to the placebo arm of add-on drug studies (SUDEP rate of 6.1 per 1000 patient years, 95% CI 3.3-10.3), 1 patients who were referred for epilepsy surgery but did not receive epilepsy surgery (SUDEP rate of 6.3 per 1000 patient years, 95% CI 1.7-16.1), 14 and patients with recurrent seizures after epilepsy surgery (SUDEP rate 6.3 per 1000 patient years, 95% CI 3.0-11.6). 15 The upper limit of the 95% CI for the rate of SUDEP in patients treated with the RNS System is lower than the SUDEP rate reported in another study of epilepsy surgery candidates. 16 The choice to use the Annegers et al SUDEP classification system was made by the SUDEP adjudication committee, and this was the same scheme used in most studies to which we draw comparisons. Accumulating patient experience will further refine the SUDEP rate for patients treated with the RNS System. In addition, because the RNS System gathers additional data on seizures and epileptiform activity leading to death, future explorations can examine whether certain seizure patterns are particularly associated with SUDEP.
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